Latest news
Pathos AI Secures Up to $2.2 Billion Global Licensing Deal for Alphamab's First-in-Class Bispecific ADC - BioPharma APACBioPharma APAC · Wed, 05 Aug 2026 18:30:31 GMTEyes on Asia: Axiom, Pathos AI, Samsung Biologics - BioXconomyBioXconomy · Tue, 04 Aug 2026 15:19:19 GMTPathos AI to license experimental breast cancer drug from China's Jiangsu Alphamab Biopharmaceutical - ReutersReuters · Tue, 04 Aug 2026 02:42:29 GMT